Biomea Fusion (BMEA) risk factors
Item 1A of every Biomea Fusion, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
96 risks, 4 new, 14 dropped, 19 reworded since the prior year. Biomea Fusion added new operational disclosures covering pandemics, public company employee counts, and ESG compliance. The company clarified its competitive positioning in irreversible covalent menin binders and resolved a Nasdaq audit committee deficiency by appointing Julianne Averill.
Filed Mar 24, 2026 - FY2024 10-K risk factors
106 risks. Biomea Fusion is a clinical-stage biotech focused on covalent inhibitors like icovamenib and BMF-500 for diabetes and obesity. The company faces a going concern risk, zero revenues, and a June 2024 FDA clinical hold. Heavy reliance on the unproven FUSION System and intense capital needs dominate its risk profile.
Filed Mar 31, 2025